Ocuphire Pharma Investor Day Presentation Deck
DR
DME
VEGF
APX3330 reduces VEGF protein
expression
in preclinical stroke model
In vitro Validation of APX3330 Mechanism of Action
APX3330 Reduces VEGF levels and Inflammatory Cytokines; Provides Neuronal Protection
VEGF
13
Control
% Positive area (+SE)
2.6
1.3
0.0
0.1mm
VEGF
T1DM-MCAO
APX3330
* p<0.05
n=7/group
+APX3330
APX3330 reduces pro-inflammatory
cytokines in LPS stimulated macrophages
TNF-α
µg/mL
14000
12000
10000
8000
6000
4000
2000
0
APX3330
LPS (1 µg/mL)
14000
12000
10000
8000
6000
4000
2000
0
0 ug/mL
APX3330
LPS (1µg/mL)
0 ug/mL
+
6.3 ug/mL 12.5 ug/mL 25 ug/mL
+
0 ug/mL 0 ug/mL
+
IL-6
25 ug/mL
+
Increasing APX3330 dose
+
6.3 ug/mL 12.5 ug/mL
+
+
% increase in APE1 repair activity
APX3330 increases DNA oxidative
repair and neuronal protection
120
115
110
105
100
95
N=4
*+
12.5
25
APX3330 (μm)
-Tao Yan et al. APX3330 Promotes Neurorestorative effects after stroke in type one diabetic rats. Aging and Disease. Vol 9, Oct 2018
-Apurinic/Apyrimidinic endonuclease 1 regulates inflammatory response in macrophages. Jedinak A, Dudhgaonkar S, Kelley MR, Sliva D. Anticancer Res. 2011 Feb;31(2):379-85. PMID: 21378315
-Fehrenbacher, J. C., Guo, C., Kelley, M. R. & Vasko, M. R. DNA damage mediates changes in neuronal sensitivity induced by the inflammatory mediators, MCP-1 and LPS, and can be reversed by enhancing the DNA
repair function of APE1. Neuroscience 366, 23-35, doi:10.1016/j.neuroscience.2017.09.039 (2017).
*H
50
APX3330 enhances Ref-1
endonuclease activity in dorsal
root ganglion neurons
Ocuphire
PHARMAView entire presentation